All In Biotech

Drug Trial Radar · NCT06991556

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

168

Actual

Start

Jul 7, 2025

Primary completion

Dec 3, 2026

Study completion Oct 18, 2035

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from participants randomized in the study will be evaluated

Conditions

  • Metastatic Hormone-sensitive Prostate Cancer

Interventions

  • JSB462Drug

    JSB462 is administered orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.

  • AbirateroneDrug

    Abiraterone 1000 mg is administered orally, daily and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.

  • EnzalutamideDrug

    Enzalutamide 160 mg is administered orally, daily and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prostate Specific Antigen 90 (PSA90) RateTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months
  2. Incidence rate of adverse events (AEs)Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months
  3. Number of participants with dose adjustmentsTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months
  4. Duration of exposure to study treatmentTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months

Locations

64 sites in 15 countries. Site status is shown where the registry gives one.

  • University of California San Diego - Moores Cancer Center

    La Jolla, California

  • Saint Johns Cancer Institute

    Santa Monica, California

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • Advanced Urology Ins Daytona Beach

    Daytona Beach, Florida

  • Emory University School of Medicine-Winship Cancer Institute

    Atlanta, Georgia

  • Associated Urological Specialists

    Chicago Ridge, Illinois

  • Mass General Hospital

    Boston, Massachusetts

  • Michigan Institute of Urology

    West Bloomfield, Michigan

  • XCancer Omaha LLC

    Omaha, Nebraska

  • Perlmutter Cancer Centre

    New York, New York

  • Associated Med Professionals of NY

    Syracuse, New York

  • Montefiore Medical Center

    The Bronx, New York

  • MidLantic Urology

    Bala-Cynwyd, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Tennessee Oncology

    Nashville, Tennessee

  • Urology San Antonio

    San Antonio, Texas

  • Inova Schar Cancer Institute

    Fairfax, Virginia

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Fred Hutch Cancer Research

    Seattle, Washington

  • Novartis Investigative Site

    Adelaide, South Australia, Australia

  • Novartis Investigative Site

    Clayton, Victoria, Australia

  • Novartis Investigative Site

    Fortaleza, Ceará, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Halifax, Nova Scotia, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, Chaoyang, China

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Olomouc, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Quint-Fonsegrives, France

  • Novartis Investigative Site

    Suresnes, France

  • Novartis Investigative Site

    Nice, Alpes Maritimes, France

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Lübeck, Germany

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.